Cynata Therapeutics see their organ rejection study published

Company News

by Rachael Jones

Clinical-stage biotechnology company Cynata Therapeutics (ASX:CYP) is excited to have a scientific paper published on the efficacy of Cymerus MSCs in a preclinical model of organ transplant rejection.

The report will be published in Stem Cell Research & Therapy.

Cymerus also limits injury to the transplanted organ.

The treatment led to an i ncrease in human TSG-6, an anti-inflammatory protein, followed by an increase in peripheral mouse regulatory T cells, which play an important role in limiting transplant rejection by establishing immune tolerance.

Shares in Cynata Therapeutics (ASX:CYP) closed -0.93 per cent lower at $1.60 yesterday.
 

Are you a 708 sophisticated investor?

A sophisticated investor is defined under Section 708 of the Corporations Act (net assets of $2.5 million or annual incomes in excess of $250,000).

They are eligible to receive information regarding wholesale investment opportunities that are not available to regular or retail investors.

Please subscribe if you would like to be alerted to these types of opportunities.